Your browser doesn't support javascript.
loading
Streamlined plug-in aerosol prototype for reconfigurable manufacture of nano-drug delivery systems.
Maharjan, Srijan; Gautam, Milan; Poudel, Kishwor; Yong, Chul Soon; Ku, Sae Kwang; Kim, Jong Oh; Byeon, Jeong Hoon.
Afiliação
  • Maharjan S; College of Pharmacy, Yeungnam University, Gyeongsan, 38541, Republic of Korea.
  • Gautam M; College of Pharmacy, Yeungnam University, Gyeongsan, 38541, Republic of Korea.
  • Poudel K; College of Pharmacy, Yeungnam University, Gyeongsan, 38541, Republic of Korea.
  • Yong CS; College of Pharmacy, Yeungnam University, Gyeongsan, 38541, Republic of Korea.
  • Ku SK; College of Korean Medicine, Daegu Haany University, Gyeongsan, 38610, Republic of Korea.
  • Kim JO; College of Pharmacy, Yeungnam University, Gyeongsan, 38541, Republic of Korea. Electronic address: jongohkim@yu.ac.kr.
  • Byeon JH; School of Mechanical Engineering, Yeungnam University, Gyeongsan, 38541, Republic of Korea. Electronic address: postjb@yu.ac.kr.
Biomaterials ; 284: 121511, 2022 05.
Article em En | MEDLINE | ID: mdl-35398587
ABSTRACT
The significant advances in nano-drug delivery systems (NDDS) for anticancer agents have led to the development of computational techniques, such as machine learning and neural networks to identify the optimal architectural and compositional design in a wide variety of therapeutic nanoformulations. On the other hand, few studies have examined downsized plug-in reaction-ware embodied in an autonomous platform for the instant reconfigurable production of engineered nanomaterials to guide optimal NDDS designs and delivery strategies. This paper describes an on-demand system for an electrically operable, continuously processible material produced by sequential spray pyrolysis and vibrating spray for single-pass NDDS assembly. In particular, a mild chemotherapeutic NDDS consisting of amorphous boron nitride (a-BN; a stable base material for loading), doxorubicin (DOX; an anticancer drug), and folic acid-chitosan conjugate (FACHI; a targeting and antiopsonic agent), called a-BN-DOX@FACHI, was fabricated using the developed system. a-BN-DOX@FACHI was assessed for the pH-responsive release of DOX, targeting of the folate receptor, and its resistance to opsonization and macrophage phagocytosis. a-BN-DOX@FACHI was found to be a mild cancer chemotherapeutic with reasonable biosafety. Integrating a metal ablation device with the developed on-demand system enabled the reconfiguration of NDDS from a-BN-DOX@FACHI to a-BN-Au-DOX@FACHI or a-BN-Pt-cisplatin@bovine serum albumin to add a photothermal effect with a range of architectures and compositions.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sistemas de Liberação de Medicamentos / Antineoplásicos Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sistemas de Liberação de Medicamentos / Antineoplásicos Idioma: En Ano de publicação: 2022 Tipo de documento: Article